JMP Securities Maintains Market Outperform on Evolent Health, Lowers Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Constantine Davides maintains a Market Outperform rating on Evolent Health (NYSE:EVH) but lowers the price target from $34 to $31.
August 09, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on Evolent Health but lowers the price target from $34 to $31.
The Market Outperform rating suggests continued confidence in Evolent Health's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100